- ISIN
- NL00150005Y4
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 5, 2021
Highlights
- Market Cap
- $1.96B
- Enterprise Value
- $1.63B
- EPS (TTM)
- -€2.99
- EBITDA (TTM)
- -€167.06M
- Year Range
- $16.72 - $34.41
- Target Price
- $45.60
- ROA (TTM)
- -58.28%
- ROE (TTM)
- -64.77%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PHVS Performance Chart
Pharvaris N.V. (PHVS) is up 19.6% since the beginning of the year. At $33 per share, PHVS is trading 3.5% below its 52-week high of $34. Investors who bought $1,000 worth of PHVS shares 5 years ago would now be looking at an investment worth $1,744.
Loading charts...
Returns By Period
Pharvaris N.V. (PHVS) has returned 19.60% so far this year and 90.53% over the past 12 months.
Pharvaris N.V.
- 1D
- 0.58%
- 1M
- 11.83%
- YTD
- 19.60%
- 6M
- 28.39%
- 1Y
- 90.53%
- 3Y*
- 41.97%
- 5Y*
- 11.76%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
PHVS Monthly Returns History
Based on dividend-adjusted daily data since Feb 5, 2021, PHVS's average daily return is +0.30%, while the average monthly return is +6.94%. At this rate, an investment would double in approximately 0.9 years.
Historically, 45% of months were positive and 55% were negative. The best month was Dec 2022 with a return of +433.2%, while the worst month was Aug 2022 at -58.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, PHVS closed higher 47% of trading days. The best single day was Dec 8, 2022 with a return of +356.6%, while the worst single day was Aug 22, 2022 at -34.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.52% | 4.95% | -0.49% | 9.77% | -2.74% | 10.05% | 19.60% | ||||||
| 2025 | -8.19% | -9.66% | -1.26% | 17.71% | -10.17% | 6.02% | 12.95% | 8.90% | 15.24% | -10.94% | 27.72% | -2.22% | 44.76% |
| 2024 | 6.60% | -23.28% | 0.74% | 6.40% | -22.90% | -0.84% | -8.83% | 5.02% | 2.89% | 34.29% | -11.94% | -12.47% | -31.66% |
| 2023 | -20.00% | -10.06% | -0.49% | 16.08% | -8.02% | 76.05% | 12.29% | 20.59% | 1.80% | -18.50% | 1.18% | 62.99% | 149.33% |
| 2022 | 19.46% | -0.52% | 6.05% | -5.77% | 5.29% | 22.82% | -1.15% | -58.39% | -15.62% | -39.37% | -54.62% | 433.18% | -21.82% |
| 2021 | 51.96% | -26.35% | -13.87% | -14.94% | -9.12% | -4.62% | 13.62% | -12.18% | -1.69% | -15.61% | -2.18% | -42.44% |
Benchmark Metrics
Pharvaris N.V. has an annualized alpha of 95.78%, beta of 0.54, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 05, 2021.
- This stock tended to rise when S&P 500 Index fell (downside capture of -264.11%), but participation in market rallies was also limited (-46.67%) - a profile typical of counter-cyclical assets.
- Beta of 0.54 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 95.78%
- Beta
- 0.54
- R²
- 0.00
- Upside Capture
- -46.67%
- Downside Capture
- -264.11%
Return for Risk
Risk / Return Rank
PHVS ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Pharvaris N.V. (PHVS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PHVS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.34 | ||
| Sortino ratioReturn per unit of downside risk | -0.08 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.32 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 4.15 | 2.46 | +1.69 |
| Martin ratioReturn relative to average drawdown | 9.29 | 10.92 | -1.63 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pharvaris N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pharvaris N.V. was 95.06%, occurring on Dec 2, 2022. The portfolio has not yet recovered.
The current Pharvaris N.V. drawdown is 17.25%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -95.06%Dec 2022 | 1y 9mo | — | 5y 3moFeb 2021 - now |
2021 correction2021 | -16.36%Feb 2021 | 6d | 2d | 8dFeb 2021 - Feb 2021 |
2021 correction2021 | -12.20%Feb 2021 | 1d | 1d | 2dFeb 2021 - Feb 2021 |
2021 pullback2021 | -1.03%Feb 2021 | 0s | 1d | 1dFeb 2021 - Feb 2021 |
Drawdown Indicators
| PHVS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.06% | -56.78% | -38.28% |
Max Drawdown (1Y)Largest decline over 1 year | -21.93% | -9.10% | -12.83% |
Max Drawdown (3Y)Largest decline over 3 years | -63.11% | -18.90% | -44.21% |
Max Drawdown (5Y)Largest decline over 5 years | -92.80% | -25.43% | -67.37% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -17.25% | -3.21% | -14.04% |
Average DrawdownAverage peak-to-trough decline | -52.59% | -10.71% | -41.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.78% | 2.04% | +7.74% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pharvaris N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pharvaris N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PHVS in comparison with other companies in the Biotechnology industry. Currently, PHVS has a P/B value of 6.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PHVS
Add Pharvaris N.V. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PHVS